Whitepapers

Aug 23, 2016
Pharmaceutical Executive
Pharm Exec talks to Mollie Shields-Uehling, a leading advocate for high-assurance identity trust for cyber-transactions in the biopharmaceutical industry. Read our executive summary covering topics like cyber/technical security; eHealth regulatory compliance; work flow automation, the benefits of eSignature programs, and collaboration around key aspects of drug development like the administration of clinical trials and research partnering.
Jul 22, 2016
Pharmaceutical Executive
By
Drug pricing is a constant hum in the news, begging the question are drug prices really too high? This white paper aims to parse out the real issues at play in the biopharmaceutical market and examine what dynamics are occurring by using oncology in the United States as a case study.
Jul 19, 2016
Sponsored Content
According to Global Genes, more than 350 million people worldwide suffer from rare diseases. Unfortunately, according to the FDA’s Every Life Foundation, only around 5% of rare diseases have a FDA-approved treatment.Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, has worked on more than 245 rare disease studies in 96 countries since 2010. Here, Laurie Witherwax outlines the patient-centric approach that Quintiles deploys to help pharmaceutical and biotechnology companies get new therapies to patients.
Jun 03, 2016
Pharmaceutical Executive
By leveraging co-pay support programs as front-end patient acquisition tactics, marketers can use them as a means of engaging patients in the brand’s integrated and multifaceted marketing stream
May 31, 2016
Pharmaceutical Executive
By
Medication adherence is a broadly recognized problem that compromises both clinical and economic outcomes of drug treatments. Medication adherence is also a problem with a solution. The use of what is often called “smart packing,” standard pharmaceutical packages with an embedded microchip to detect opening and closing, can give healthcare providers key information on precisely when each dose was taken—or when it was missed. The ability to identify and quantify both adherence and nonadherence promises to improve clinical outcomes and reduce overall healthcare spending.
Apr 20, 2016
Pharmaceutical Executive
By
The all-new 2016 Chevrolet Malibu offers exceptional style, safety, and efficiency that will be popular with reps and desirable for fleet managers. Read this whitepaper and infographic that demonstrate the features and technologies that make Chevrolet Malibu a great option for pharma fleets.
Apr 18, 2016
Pharmaceutical Executive
By
How can you get your drug to market faster? Join Hewlett Packard Enterprise and Linguamatics as they discuss accelerating your company’s data analytics capabilities. This Executive Summary will provide case studies that illustrate how you can use analytics across the drug development pipeline to support better-informed business decisions and gain competitive advantage.
Apr 07, 2016
Pharmaceutical Executive
With the deadline for EFPIA reporting quickly approaching (on or before June 30, 2016) life sciences organizations leaning on best practices and learnings they have gleaned from the Open Payments Program a.k.a. Sunshine Act. As the relationships between industry and healthcare professionals are often in question, financial disclosure programs showcasing ‘transfers of value’ or forms of remuneration to the HCP is growing to further enable trust between patients, physicians and life sciences. This white paper explores the similarities of what data needs to be captured and available for reporting as well as highlights the differences and challenges of implementing a non-mandated program.
Apr 06, 2016
Pharmaceutical Executive
Marketing to physicians is evolving at light speed—are you taking advantage of the latest technologies and platforms to target physicians? MDalert.com’s new white paper provides an overview of the dynamic landscape in micro-targeting physicians, as well as evidence that our new mobile-optimized digital platform drives physician engagement in this era of performance-driven healthcare.
Apr 01, 2016
Pharmaceutical Executive
This paper examines the changing environment for marketed, or established, products. Authors discuss emerging markets, recent divestment discussions, challenges in the current model — and a proposed solution for how biopharmaceutical companies can more effectively manage the routine maintenance required to maximize the value of these product portfolios.
native1_300x100
also read

читать далее
lorem ipsum